Welcome To The Bioniche Life Sciences HUB On AGORACOM

Edit this title from the Fast Facts Section


BREAKING: Esports Entertainment Group Releases Upgraded VIE.GG Esports Gambling Platform

  • Announced the release of the latest version of VIE.gg (https://vie.gg)  the Company’s esports wagering platform
  • Latest upgrade delivers notable new features, including additional betting options such as Fixed Odds, Pari-mutuel, Fantasy and Pool Betting to complement main P2P option
  • Grant Johnson, CEO of Esports Entertainment Group, stated "This is another major milestone for our Company. This is our strongest release ever, with every new feature esports gambling enthusiasts could wish for in a platform..."
Message: Offering, to complete the filing of Biologics Licence Application with FDA

Matter of a short time to real money, it seems


Bioniche Life Sciences Inc. has released the terms of its previously announced overnight marketed public offering with a syndicate of agents led by Dundee Securities Ltd., and including Clarus Securities Inc. and Euro Pacific Canada Inc. In connection with the Offering, Bloom Burton & Co. Inc. has been appointed as a selling group member.

The Offering will consist of 21,800,000 units of the Company (the "Units"), each Unit consisting of one common share (each, a "Share") and one-half of one common share purchase warrant (each, a "Warrant" and together, the "Warrants") at a price per Unit of $0.23 (the "Offering Price") for aggregate gross proceeds of $5,014,000. Each whole Warrant will entitle the holder thereof to acquire one Share of the Company at a price per Share of $0.30 for a period of 60 months following the issuance thereof.

The Company plans to file an amended preliminary prospectus today reflecting the terms herein. The Offering is scheduled to close on or about September 10, 2014. The Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals.

The net proceeds of the Offering will be used by the Company to complete the filing with the United States Food & Drug Administration (FDA) of a Biologics License Application (BLA) for their lead program Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed Bacillus Calmette-Guerin (BCG) therapy, and for working capital and general corporate purposes.

We seek Safe Harbor.

New Message
Please login to post a reply